For research use only. Not for therapeutic Use.
SRX3177(CAT: I036641) is a potent triple inhibitor targeting CDK4/6, PI3K, and BRD4, demonstrating strong inhibitory activity with IC50 values of 33 nM (BRD4 BD1), 89 nM (BRD4 BD2), 79 nM (PI3Kα), 83 nM (PI3Kδ), 3.18 μM (PI3Kγ), <2.5 nM (CDK4), and 3.3 nM (CDK6). By inhibiting these key proteins, SRX3177 disrupts crucial signaling pathways involved in cell cycle regulation, survival, and transcription, making it a potent agent in cancer research. Despite its broad cytotoxic activity against cancer cells, SRX3177 shows minimal toxicity toward normal epithelial cells, highlighting its potential for targeted cancer therapy. This compound is particularly relevant for Cancer Disease Research, offering a promising approach for treating various cancer types while minimizing damage to healthy tissues.
| CAS Number | 2241237-51-2 |
| Synonyms | 7-cyclopentyl-N,N-dimethyl-2-[4-(5-morpholin-4-yl-7-oxothieno[3,2-b]pyran-3-yl)anilino]pyrrolo[2,3-d]pyrimidine-6-carboxamide |
| Molecular Formula | C31H32N6O4S |
| Purity | ≥95% |
| IUPAC Name | 7-cyclopentyl-N,N-dimethyl-2-[4-(5-morpholin-4-yl-7-oxothieno[3,2-b]pyran-3-yl)anilino]pyrrolo[2,3-d]pyrimidine-6-carboxamide |
| InChI | InChI=1S/C31H32N6O4S/c1-35(2)30(39)24-15-20-17-32-31(34-29(20)37(24)22-5-3-4-6-22)33-21-9-7-19(8-10-21)23-18-42-28-25(38)16-26(41-27(23)28)36-11-13-40-14-12-36/h7-10,15-18,22H,3-6,11-14H2,1-2H3,(H,32,33,34) |
| InChIKey | XJKTXWSMMWPNTP-UHFFFAOYSA-N |
| SMILES | CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=CC=C(C=C4)C5=CSC6=C5OC(=CC6=O)N7CCOCC7 |
